Skip to content
Review Open access

RNA-Binding Motif Protein 3 as a Therapeutic and Prognostic Target for Drug Discovery

Aug 2026 · Current Issues in Molecular Biology · Vol 48, pp. 815 · 0 citations · 97 references
Medicine

TL;DR

This comprehensive literature review delves into the multifaceted roles of RNA-binding motif protein 3 in cellular processes, disease pathogenesis, and therapeutic potential and underscores the pivotal role of RBPs, particularly RBM3, in disease progression and highlights the need for continued investigation to harness their therapeutic potential effectively.

Abstract

This comprehensive literature review delves into the multifaceted roles of RNA-binding motif protein 3 (RBM3) in cellular processes, disease pathogenesis, and therapeutic potential. RBM3 has been implicated in shaping cell morphology, synaptic protection in neurodegenerative conditions, and regulating gene expression through binding to specific RNA sequences. In cancer, RBM3 exhibits contrasting effects, influencing cell proliferation, tumorigenic potential, and RNA splicing. Clinical studies suggest RBM3 as a predictive biomarker in chemotherapy response for muscle-invasive bladder cancer. Despite promising therapeutic implications in neuroprotection and cancer, challenges persist in understanding the regulatory mechanisms and clinical behavior of RBM3. Further research is warranted to elucidate the molecular mechanisms underlying RBM3’s diverse functions and its significance as a potential target for personalized medicine in cancer therapy. This review underscores the pivotal role of RBPs, particularly RBM3, in disease progression and highlights the need for continued investigation to harness their therapeutic potential effectively. This review evaluates evidence available through December 2025, with particular emphasis on studies published between 2010 and 2025.

Read PDF

Similar papers

Review Open access Aug 2026

Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery

This review describes the structural organization of IGF2BP3, the molecular basis of RNA recognition, and the mechanisms underlying its dysregulation across human cancers and discusses emerging therapeutic approaches, including direct inhibition of IGF2BP3–RNA interactions and indirect strategies that rewire IGF2BP3 ex...

Elisa Uliassi, M. Bolognesi, K. Scotlandi et al. · 0 citations
Review Sep 2026

Protein-protein interactions as therapeutic targets in breast cancer: integrated computational and experimental advances, mechanisms and clinical translation

This review systematically summarizes the core regulatory mechanisms of PPIs in breast cancer, focusing on neomorphic interactions (neoPPIs) and hypomorphic interactions (hypoPPIs) induced by driver mutations, and dissecting their regulatory effects on key pathways such as apoptotic pathways, DNA damage repair, and hor...

Kui Liu, Yong Yang, Hong Yang et al. · 0 citations
Open access Jul 2026

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors

Beyond enabling the discovery of several new potent and selective small molecules, these studies have allowed us to elucidate key parameters for potency, selectivity, and metabolic stability that should aid future efforts in RBP drug discovery.

G. M. Scherer, Jacob P. Sorrentino, A. K. Jaiswal et al. · 0 citations
Review Open access Aug 2026

SKP2 in Cancer: From Molecular Regulation to Therapeutic Vulnerabilities and Translational Perspectives

Emerging evidence has expanded the functional repertoire of SKP2 beyond cell cycle control to encompass metabolism, DNA repair, stemness, tumor microenvironment and immunotherapy response, positioning it as an increasingly attractive target for intervention.

Sheng-An Zheng, Cheng Wang, Xiao-Die Yao et al. · 0 citations
Review Open access Jul 2026

The functions, mechanisms and clinical relevance of RNA and protein acetyltransferase NAT10: a comprehensive review.

The molecular mechanisms underlying NAT10-mediated RNA ac4C modification and protein acetylation, as well as their biological functions across physiological and pathological contexts, are systematically summarized, with the aim of facilitating its clinical translation.

Chengyu Zhang, Jin Lu, Lu Tang et al. · 0 citations
Review Aug 2026

Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact.

The molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis, its role in super-enhancer-driven oncogenic programs, and the mechanisms by which CDK9 inhibition promotes apoptosis, epigenetic derepression, and tumor microenvironment remodeling are summarized.

Ti-Yao Liu, Zhongran Liu, Wen-Jing Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.